C. Lienhardt

F. Cobelens, C. Lienhardt, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa.

R. Adegbola, P. Aaby, S. Bennett, 2005, International journal of epidemiology.

Introducing risk inequality metrics in tuberculosis policy development

M. Gomes, R. Duarte, P. Shete, 2018, Nature Communications.

Mycetomas in Mali: causative agents and geographic distribution.

S. Keita, C. Lienhardt, M. Develoux, 1996, The American journal of tropical medicine and hygiene.

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.

R. Adegbola, H. McShane, A. Hill, 2006, The Lancet. Infectious diseases.

Is operational research delivering the goods? The journey to success in low-income countries.

N. Ford, R. Atun, K. Castro, 2012, The Lancet. Infectious diseases.

Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.

Shabir Madhi, Beate Kampmann, Christian Lienhardt, 2012, The Journal of infectious diseases.

Factors affecting time delay to treatment in a tuberculosis control programme in a sub-Saharan African country: the experience of The Gambia.

P. Milligan, K. McAdam, C. Lienhardt, 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Methodological and reporting quality of systematic reviews on tuberculosis.

M. Pai, C. Lienhardt, D. Ling, 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

S. Shah, K. Dooley, A. Diacon, 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Evaluation of the Prognostic Value of IFN-γ Release Assay and Tuberculin Skin Test in Household Contacts of Infectious Tuberculosis Cases in Senegal

J. Gomis, S. Mboup, K. Fielding, 2010, PloS one.

Improving tuberculosis control: an interdisciplinary approach

R. Rustomjee, C. Lienhardt, 2006, The Lancet.

Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance

P. Nahid, M. Cavaleri, A. Vernon, 2019, PLoS medicine.

Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa

G. Sirugo, A. Hill, S. J. Campbell, 2006, Proceedings of the National Academy of Sciences.

New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes

M. Raviglione, A. Vernon, C. Lienhardt, 2010, Current opinion in pulmonary medicine.

Advances in clinical trial design for development of new TB treatments: A call for innovation

P. Nahid, C. Lienhardt, 2019, PLoS medicine.

Target regimen profiles for treatment of tuberculosis: a WHO document

P. Nahid, G. Churchyard, E. Kendall, 2017, European Respiratory Journal.

Title Target regimen profiles for treatment of tuberculosis : a WHO document Permalink

P. Nahid, G. Churchyard, E. Kendall, 2017 .

Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing: A Needs Assessment and Roadmap for Action

Colleen, M. Perkins, F. Cobelens, 2014 .

Tuberculosis 2013 : 4 Alignment of new tuberculosis drug regimens and drug susceptibility testing : a framework for action

M. Perkins, F. Cobelens, M. Pai, 2013 .

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model

K. Dooley, D. Dowdy, T. Cohen, 2017, PLoS medicine.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

E. Kurbatova, M. L. van der Walt, C. Kvasnovsky, 2015, The Lancet. Respiratory medicine.

WHO target product profiles for TB preventive treatment

N. Arinaminpathy, P. Nahid, G. Churchyard, 2022, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness

N. Arinaminpathy, D. Falzon, K. Schwartzman, 2022, PLoS medicine.

Interleukin-8 polymorphism is not associated with pulmonary tuberculosis in the gambia.

G. Sirugo, G. Cooke, A. Hill, 2004, The Journal of infectious diseases.

Tuberculosis drug development: ensuring people living with HIV are not left behind.

D. Havlir, A. Luetkemeyer, H. Getahun, 2011, American journal of respiratory and critical care medicine.

Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18 q 11 . 2

A. Morris, S. Wong, M. Newport, 2019 .

First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea

L. Rigouts, E. Nduwamahoro, Cécile Uwizeye, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Advancing the development of tuberculosis therapy

M. Hoelscher, Alimuddin Zumla, A. Nunn, 2012, Nature Reviews Drug Discovery.

Identifying barriers to effective tuberculosis control in Senegal: an anthropological approach.

C. Lienhardt, A. Fall, S. Thiam, 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Clinical and radiological presentation of 340 adults with smear-positive tuberculosis in The Gambia.

R. Adegbola, K. McAdam, P. Hill, 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation

F. Blasi, M. Raviglione, C. Lienhardt, 2014, European Respiratory Journal.

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

John L. Johnson, P. Nahid, K. Fielding, 2018, Nature Medicine.

Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries

R. Chaisson, N. Schluger, T. Nyirenda, 2007, PLoS medicine.

Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.

A. Van Deun, A. Harries, P. Clevenbergh, 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

From latent to patent: rethinking prediction of tuberculosis.

F. Cobelens, A. Matteelli, H. Esmail, 2017, The Lancet. Respiratory medicine.

Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research

D. Sculier, H. Getahun, C. Lienhardt, 2011, Journal of the International AIDS Society.

CD209 Genetic Polymorphism and Tuberculosis Disease

G. Sirugo, F. Vannberg, C. Khor, 2008, PloS one.

Would pan-tuberculosis treatment regimens be cost-effective?

D. Dowdy, E. Kendall, C. Lienhardt, 2018, The Lancet. Respiratory medicine.

A functional variant in TIRAP , also known as MAL , and protection against invasive pneumococcal disease , bacteraemia , malaria and tuberculosis

D. Kwiatkowski, F. Vannberg, R. Davies, 2009 .

Identifying the determinants of tuberculosis control in resource-poor countries: insights from a qualitative study in The Gambia.

K. McAdam, C. Lienhardt, J. Ogden, 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12.

J. Vekemans, M. D’Elios, A. Marchant, 2001, American journal of respiratory cell and molecular biology.

The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis

H. Zar, R. Long, A. Garcia-Basteiro, 2020, The Lancet.

The ethics of a clinical trial when the protocol clashes with international guidelines.

N. H. Duc, T. T. Lien, A. Harries, 2013, Public health action.

Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in The Gambia.

K. McAdam, C. Lienhardt, G. Lahai, 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Harnessing the Power of Data to Guide Local Action and End Tuberculosis

K. Floyd, C. Sismanidis, P. Shete, 2017, The Journal of infectious diseases.

Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia.

R. Adegbola, K. McAdam, K. Fielding, 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo

M. D’Elios, R. Manetti, A. Amedei, 2002, European journal of immunology.

Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in west Africans.

A. Hill, S. Meisner, C. Lienhardt, 2001, The American journal of tropical medicine and hygiene.

Mercury Biomagnification Through a Coral Reef Ecosystem

M. Parsons, C. Lienhardt, D. Rumbold, 2018, Archives of Environmental Contamination and Toxicology.

Analysis of the effects on the QT interval of a gatifloxacin-containing regimen 1 versus standard treatment of pulmonary tuberculosis 2

P. Olliaro, C. Merle, K. Fielding, 2018 .

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis

P. Olliaro, C. Merle, K. Fielding, 2017, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.

L. Rigouts, A. Nunn, C. Lienhardt, 2011, JAMA.

Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared With Separate Drugs for Treatment of Pulmonary Tuberculosis

L. Rigouts, A. Nunn, C. Lienhardt, 2011 .

Defining a Migrant-Inclusive Tuberculosis Research Agenda to End TB 2

M. V. D. Werf, P. Shete, A. Matteelli, 2019 .

Simulations Pulmonary Tuberculosis Patients by Using Gatifloxacin Pharmacokinetics and Dose in Evaluation of Initial and Steady-State

Monte Carlo, R. Rustomjee, C. Merle, 2013 .

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

A. Simon, R. Adegbola, H. McShane, 2008, PloS one.

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

R. Adegbola, H. McShane, A. Hill, 2011, PLoS ONE.

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

R. Adegbola, H. McShane, A. Hill, 2008, PloS one.

Immune Responses to Mycobacterial Antigens in the Gambian Population: Implications for Vaccines and Immunodiagnostic Test Design

J. Vekemans, A. Marchant, K. McAdam, 2004, Infection and Immunity.

An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease

F. Cobelens, C. Denkinger, G. Churchyard, 2018, European Respiratory Journal.

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis

N. Arinaminpathy, D. Falzon, G. Churchyard, 2022, BMC Medicine.

Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2

A. Morris, S. Wong, D. Kwiatkowski, 2010, Nature Genetics.

Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia.

R. Adegbola, F. Drobniewski, K. McAdam, 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis.

A. Garcia-Basteiro, J. Andrews, C. Stein, 2022, The Lancet. Global health.

A bibliometric analysis of tuberculosis research, 2007–2016

M. Pai, C. Lienhardt, T. Pande, 2018, PloS one.

Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia.

K. McAdam, K. Fielding, C. Lienhardt, 2003, American journal of respiratory and critical care medicine.

Global tuberculosis drug development pipeline: the need and the reality

A. Nunn, C. Lienhardt, H. McIlleron, 2010, The Lancet.

Global tuberculosis control: lessons learnt and future prospects

Philippe Glaziou, Christian Lienhardt, M. Uplekar, 2012, Nature Reviews Microbiology.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

R. Chaisson, S. Dorman, J. Brożek, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

R. Chaisson, S. Dorman, J. Brożek, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bactericidal Activity of a Single-Dose Combination of Ofloxacin plus Minocycline, with or without Rifampin, against Mycobacterium leprae in Mice and in Lepromatous Patients

B. Ji, J. Grosset, C. Lienhardt, 1998, Antimicrobial Agents and Chemotherapy.

Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients

B. Ji, J. Grosset, C. Lienhardt, 1996, Antimicrobial agents and chemotherapy.

Analysis of the clinical antibacterial and antituberculosis pipeline.

John H Rex, Stephan Harbarth, Peter Beyer, 2019, The Lancet. Infectious diseases.

Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation?

P. Fine, C. Lienhardt, 1994, Leprosy review.

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

L. Czaplewski, C. Arias, S. Harbarth, 2022, Antimicrobial agents and chemotherapy.

Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review

Rifat Atun, Christian Lienhardt, F. Cobelens, 2012, PLoS medicine.

Does chloroquine resistance occur in refugee camps in eastern Sudan?

C. Lienhardt, E. Candolfi, R. Ghebray, 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design.

M. Newport, K. McAdam, C. Lienhardt, 2002, American journal of epidemiology.

Childhood tuberculosis: progress requires an advocacy strategy now

Andreas Sandgren, Beate Kampmann, Christian Lienhardt, 2012, European Respiratory Journal.

Tuberculosis in Brazil and cash transfer programs: A longitudinal database study of the effect of cash transfer on cure rates

M. Gomes, B. Reis-Santos, P. Shete, 2019, PloS one.

A four-month gatifloxacin-containing regimen for treating tuberculosis.

B. D. de Jong, C. Sismanidis, P. Olliaro, 2015, The New England journal of medicine.

Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial.

A. Ndiaye, K. Fielding, C. Lienhardt, 2007, JAMA.

From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis.

C. Lienhardt, C Lienhardt, 2001, Epidemiologic reviews.

WHO's new End TB Strategy

Christopher Gilpin, Philippe Glaziou, Dennis Falzon, 2015, The Lancet.

BCG: the story continues

Alimuddin Zumla, C. Lienhardt, 2005, The Lancet.

Sensitivity of IFN-γ Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS Progression

S. Mboup, P. Sow, H. Fletcher, 2008, PloS one.

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

H. Schünemann, E. Caumes, N. Veziris, 2019, Emerging infectious diseases.

CISH and susceptibility to infectious diseases.

S. Wong, J. Sung, D. Kwiatkowski, 2010, The New England journal of medicine.

A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis

Giorgio Sirugo, Kevin Marsh, James A Berkley, 2007, Nature Genetics.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

M. D. Granado, T. Holtz, K. Floyd, 2011, European Respiratory Journal.

A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients

Akash Khandelwal, P. Olliaro, R. Rustomjee, 2012, Antimicrobial Agents and Chemotherapy.

Type 1 reac tion, neuritis and dis ability in lepr osy. What is the current epideini ological situat ion?

P. Fine, C. Lienhardt, 1994 .

Research Questions and Priorities for Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses

Madhukar Pai, Ioana Nicolau, Christian Lienhardt, 2012, PloS one.

Questions and Priorities for Tuberculosis : A Survey of Published Systematic Reviews and Meta-Analyses

M. Pai, C. Lienhardt, D. Ling, 2012 .

Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis

A. Benedetti, M. Pai, D. Menzies, 2009, PLoS medicine.

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

D. Mitchison, R. Rustomjee, G. Davies, 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Estimating the yield of tuberculosis from key populations to inform targeted interventions in South Africa: a scoping review

S. Charalambous, G. Churchyard, Nishila Moodley, 2020, BMJ Global Health.

Risk Factors for Positive Tuberculin Skin Test in Guinea-Bissau

P. Aaby, I. Lisse, C. Lienhardt, 2007, Epidemiology.

Risk factors for defaulting from tuberculosis treatment: a prospective cohort study of 301 cases in the Gambia.

W. Stevens, P. Hill, S. Donkor, 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis.

C. Horsburgh, D. McNeeley, C. Lienhardt, 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Tuberculosis Contacts but Not Patients Have Higher Gamma Interferon Responses to ESAT-6 than Do Community Controls in The Gambia

J. Vekemans, P. Andersen, A. Marchant, 2001, Infection and Immunity.

Risk of relapse in multibacillary leprosy

C. Lienhardt, S. Sow, P. Jamet, 1995, The Lancet.

Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.

L. Rigouts, A. Nunn, C. Lienhardt, 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline

C. Lienhardt, I. Frost, Pilar Garcia-Vello, 2022, The Lancet. Microbe.

Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis.

G. Sirugo, G. Cooke, P. V. van Helden, 2008, American journal of respiratory and critical care medicine.

Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo Simulations

John Horton, Wynand Smythe, Christian Lienhardt, 2013, Antimicrobial Agents and Chemotherapy.

Advances in clinical trial design: Weaving tomorrow’s TB treatments

R. Chaisson, E. Delaporte, P. Nahid, 2020, PLoS medicine.

Effect of HIV infection on leprosy: a three-year survey in Bamako, Mali.

O. Faye, C. Lienhardt, S. Sow, 1996, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Inter-observer variability in the assessment of nerve function in leprosy patients in Ethiopia.

C. Lienhardt, J. Wheeler, H. Currie, 1995, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

C. Sismanidis, P. Olliaro, F. Portaels, 2012, Trials.

Priority Areas for Research on Anti-Tuberculosis Treatment

C. Lienhardt, M. Spigelman, B. Laughon, 2021, Essential Tuberculosis.

Estimation of the impact of the human immunodeficiency virus infection on tuberculosis: tuberculosis risks re-visited?

C. Lienhardt, L. Rodrigues, 1997, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Tuberculosis Cases in The Gambia, West Africa Risk Factors for Tuberculosis Infection in Children in Contact With Infectious

K. Fielding, C. Lienhardt, S. Donkor, 2013 .

The Gambia to ESAT-6 than Do Community Controls in Have Higher Gamma Interferon Responses Tuberculosis Contacts but Not Patients

J. Vekemans, A. Marchant, K. McAdam, 2000 .

Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis

A. Benedetti, M. Pai, D. Menzies, 2009, PLoS medicine.

Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development.

C. Lienhardt, Zhenkun Ma, 2009, Clinics in chest medicine.

Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges

C. Lienhardt, M. Bonnet, Gino Agbota, 2023, Pathogens.

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials

N. Hills, P. Nahid, C. Lienhardt, 2021, Trials.

Risk factors for pulmonary tuberculosis: a clinic-based case control study in The Gambia

R. Adegbola, P. Hill, D. Jackson-Sillah, 2006, BMC public health.

Key issues in the clinical development and implementation of TB vaccines in South Africa.

S. Lockhart, W. Hanekom, H. Mahomed, 2012, Tuberculosis.

Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis.

G. Cooke, A. Hill, S. J. Campbell, 2006, American journal of respiratory and critical care medicine.

Antimicrobial Resistance in Africa—How to Relieve the Burden on Family Farmers

C. Ducrot, A. Moodley, F. Goutard, 2021, Emerging infectious diseases.

Situation analysis of TB microscopy centres in Ghana.

C. Lienhardt, D. Yeboah-Manu, K. Addo, 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Improving the laboratory diagnosis of TB in Ghana: the impact of a quality assurance system.

C. Lienhardt, D. Yeboah-Manu, K. Addo, 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda

E. Oren, F. Cobelens, C. Daley, 2016, PloS one.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions

S. Swaminathan, F. Cobelens, G. Kaplan, 2016, PLoS medicine.

Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study.

Giorgio Sirugo, Christian Lienhardt, Peter Aaby, 2004, The Journal of infectious diseases.

Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study.

B. Reis-Santos, P. Shete, C. Lienhardt, 2019, The Lancet. Global health.

Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!”

L. Czaplewski, C. Arias, S. Harbarth, 2022, Antimicrobial agents and chemotherapy.

Humoral response to Mycobacterium tuberculosis antigens in patients with tuberculosis in the Gambia.

K. McAdam, D. Menzies, C. Lienhardt, 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel.

S. Kabra, L. Dodd, S. Swaminathan, 2012, The Journal of infectious diseases.

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam

N. H. Duc, A. Harries, C. Connolly, 2014, PloS one.

Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome.

A. Van Deun, P. Clevenbergh, P. Fujiwara, 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Investigation of environmental and host-related risk factors for tuberculosis in Africa. II. Investigation of host genetic factors.

M. Newport, K. McAdam, C. Lienhardt, 2002, American journal of epidemiology.

Fundamental research is the key to eliminating TB

Christian Lienhardt, C. Lienhardt, 2014, Nature.

A four-month gatifloxacin-containing regimen for treating tuberculosis.

C. Sismanidis, P. Olliaro, R. Rustomjee, 2015, The New England journal of medicine.

Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.

C. Lienhardt, C. Sizemore, Alison M. Kraigsley, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.

F. van Leth, S. Niemann, K. Dheda, 2023, The Lancet. Infectious diseases.

Directly observed treatment for tuberculosis

C. Lienhardt, K. Manneh, J. Rowley, 1999, The Lancet.

Traditional healers participate in tuberculosis control in The Gambia.

K. McAdam, P. Hill, C. Lienhardt, 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Tuberculosis research and development: seeding the future.

Alimuddin Zumla, M. Raviglione, C. Lienhardt, 2018, The Lancet. Respiratory medicine.

Clinical research and development of tuberculosis diagnostics: moving from silos to synergy.

Wendy S Stevens, Jane Diefenbach, David Alland, 2012, The Journal of infectious diseases.

Clinical Research and Development ofTuberculosis Diagnostics: Moving From Silos toSynergy

M. Perkins, G. Ireton, C. Hamilton, 2012 .

Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case

Richard G. White, S. Madhi, H. Rees, 2022, Vaccine.

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement.

S Niemann, F. Cobelens, F. van Leth, 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Comparison of bacillary indexes in slit-skin smears, skin and nerve biopsies; a study from Malawi.

J. Sterne, P. Fine, S. Lucas, 1997, International journal of leprosy and other mycobacterial diseases.

Controlling leprosy.

P. Fine, C. Lienhardt, 1992, BMJ.

Recent advances in the treatment of tuberculosis

R. Wilkinson, K. Dheda, G. Thwaites, 2023, Clinical Microbiology and Infection.

Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

M. Hoelscher, Alimuddin Zumla, S. Gillespie, 2012, The Journal of infectious diseases.

Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis

J. Andrews, T. Cohen, A. Harries, 2023, The Lancet. Public health.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

Richard G. White, T. Holtz, J. Bayona, 2011, European Respiratory Journal.